High-dose BAFF receptor specific mAb-siRNA conjugate generates Fas-expressing B cells in lymph nodes and high-affinity serum autoantibody in a myasthenia mouse model-Reference-Cited by-同舟云学术

High-dose BAFF receptor specific mAb-siRNA conjugate generates Fas-expressing B cells in lymph nodes and high-affinity serum autoantibody in a myasthenia mouse model

Published:2017-03 Issue: Volume:176 Page:122-130
ISSN:1521-6616
Container-title:Clinical Immunology
language:en
Short-container-title:Clinical Immunology

Author:

Ibtehaj Naazneen,Huda Ruksana

Funder

Myasthenia Gravis Foundation of America Pilot Research

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference27 articles.

1. Antibody to acetylcholine receptor in myasthenia gravis: prevalence, clinical correlates, and diagnostic value;Lindstrom;Neurology,1976

2. Targeting complement system to treat myasthenia gravis;Huda;Rev. Neurosci.,2014

3. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors;Song;Nat. Biotechnol.,2005

4. A new approach for the treatment of arthritis in mice with a novel conjugate of an anti-C5aR1 antibody and C5 small interfering RNA;Mehta;J. Immunol.,2015

5. Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1;Peer;Proc. Natl. Acad. Sci. U. S. A.,2007

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Bead-Based Nonradioactive Immunoassay for Autoantibody Testing in a Mouse Model of Myasthenia Gravis;Antibodies;2024-07-01

2. RNA therapeutics history and future perspectives;Progress in Molecular Biology and Translational Science;2024

3. Development of Apoptotic-Cell-Inspired Antibody–Drug Conjugate for Effective Immune Modulation;International Journal of Molecular Sciences;2023-11-07

4. The Evolving Landscape of Antibody–Drug Conjugates: In Depth Analysis of Recent Research Progress;Bioconjugate Chemistry;2023-10-11

5. An Overview of the Development and Preclinical Evaluation of Antibody–Drug Conjugates for Non-Oncological Applications;Pharmaceutics;2023-06-24